Click here to get full coverage on LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView

LXEO Stock Price and Chart — NASDAQ:LXEO  TradingView

LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView

Click here to get full coverage on Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Yahoo Finance

Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline  Yahoo Finance

Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Yahoo Finance

Click here to get full coverage on LXEO (NASDAQ: LXEO) Form 144: Insider files to sell 3,016 vested shares - Stock Titan

LXEO (NASDAQ: LXEO) Form 144: Insider files to sell 3,016 vested shares  Stock Titan

LXEO (NASDAQ: LXEO) Form 144: Insider files to sell 3,016 vested shares - Stock Titan

Click here to get full coverage on Insider Sale: Chief Operating Officer of $LXEO Sells 3,016 Shares - Quiver Quantitative

Insider Sale: Chief Operating Officer of $LXEO Sells 3,016 Shares  Quiver Quantitative

Insider Sale: Chief Operating Officer of $LXEO Sells 3,016 Shares - Quiver Quantitative

Click here to get full coverage on Raymond James Initiates Coverage of Lexeo Therapeutics (LXEO) with Strong Buy Recommendation - Nasdaq

Raymond James Initiates Coverage of Lexeo Therapeutics (LXEO) with Strong Buy Recommendation  Nasdaq

Raymond James Initiates Coverage of Lexeo Therapeutics (LXEO) with Strong Buy Recommendation - Nasdaq

Click here to get full coverage on Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO) - Seeking Alpha

Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO)  Seeking Alpha

Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO) - Seeking Alpha

Click here to get full coverage on Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - simplywall.st

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?  simplywall.st

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - simplywall.st

Click here to get full coverage on Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 10,173 Shares of Stock - MarketBeat

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 10,173 Shares of Stock  MarketBeat

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 10,173 Shares of Stock - MarketBeat

Click here to get full coverage on Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - Yahoo Finance

Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise  Yahoo Finance

Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - Yahoo Finance

Click here to get full coverage on LXEO (NASDAQ: LXEO) Form 144 reports 3,861 shares tied to vesting - Stock Titan

LXEO (NASDAQ: LXEO) Form 144 reports 3,861 shares tied to vesting  Stock Titan

LXEO (NASDAQ: LXEO) Form 144 reports 3,861 shares tied to vesting - Stock Titan

Click here to get full coverage on Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st

Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership  simplywall.st

Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st

Click here to get full coverage on Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential - Yahoo Finance

Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential  Yahoo Finance

Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential - Yahoo Finance

Click here to get full coverage on $135M Financing: Lexeo Therapeutics prices public offering and sells 1.25M pre-funded warrants; close Oct 20, 2025 - Stock Titan

$135M Financing: Lexeo Therapeutics prices public offering and sells 1.25M pre-funded warrants; close Oct 20, 2025  Stock Titan

$135M Financing: Lexeo Therapeutics prices public offering and sells 1.25M pre-funded warrants; close Oct 20, 2025 - Stock Titan

Click here to get full coverage on Owning 44% shares,institutional owners seem interested in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), - Yahoo Finance

Owning 44% shares,institutional owners seem interested in Lexeo Therapeutics, Inc. (NASDAQ:LXEO),  Yahoo Finance

Owning 44% shares,institutional owners seem interested in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), - Yahoo Finance

Click here to get full coverage on 23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan

23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling  Stock Titan

23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan

Click here to get full coverage on Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on Biotech Lexeo to stream Feb investor talks from New York and online - Stock Titan

Biotech Lexeo to stream Feb investor talks from New York and online  Stock Titan

Biotech Lexeo to stream Feb investor talks from New York and online - Stock Titan

Click here to get full coverage on Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - Yahoo Finance

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?  Yahoo Finance

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - Yahoo Finance

Click here to get full coverage on New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - Stock Titan

New cardiology leaders join Lexeo as it backs novel cardiac RNA startup  Stock Titan

New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - Stock Titan

Click here to get full coverage on Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) - Yahoo Finance

Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)  Yahoo Finance

Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) - Yahoo Finance

Click here to get full coverage on Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com

Lexeo Therapeutics stock falls after PKP2 gene therapy data  Investing.com

Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com

Click here to get full coverage on $LXEO stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$LXEO stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$LXEO stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $LXEO Given $19 Price Target - Quiver Quantitative

New Analyst Forecast: $LXEO Given $19 Price Target  Quiver Quantitative

New Analyst Forecast: $LXEO Given $19 Price Target - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2% - Time to Sell? - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2% - Time to Sell?  MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2% - Time to Sell? - MarketBeat

Click here to get full coverage on Early trial results: new treatment shows promise in rare heart rhythm disease - Stock Titan

Early trial results: new treatment shows promise in rare heart rhythm disease  Stock Titan

Early trial results: new treatment shows promise in rare heart rhythm disease - Stock Titan

Click here to get full coverage on Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO)  Seeking Alpha

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha

Click here to get full coverage on $LXEO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

$LXEO stock is up 11% today. Here's what we see in our data.  Quiver Quantitative

$LXEO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - Bitget

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference  Bitget

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - Bitget

Click here to get full coverage on New Analyst Forecast: $LXEO Given $13.0 Price Target - Quiver Quantitative

New Analyst Forecast: $LXEO Given $13.0 Price Target  Quiver Quantitative

New Analyst Forecast: $LXEO Given $13.0 Price Target - Quiver Quantitative

Click here to get full coverage on H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program - Insider Monkey

H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program  Insider Monkey

H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program - Insider Monkey

Click here to get full coverage on Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? - Yahoo Finance

Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday?  Yahoo Finance

Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? - Yahoo Finance

Click here to get full coverage on Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView

Lexeo Therapeutics, Inc. SEC 10-Q Report  TradingView

Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating - Investing.com

Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating  Investing.com

Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating - Investing.com

Click here to get full coverage on Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative

Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine  Quiver Quantitative

Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative

Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco  Quiver Quantitative

Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative

Click here to get full coverage on Stifel lowers Lexeo Therapeutics stock price target to $18 on offering - Investing.com

Stifel lowers Lexeo Therapeutics stock price target to $18 on offering  Investing.com

Stifel lowers Lexeo Therapeutics stock price target to $18 on offering - Investing.com

Click here to get full coverage on Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process  Stocktwits

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits

Click here to get full coverage on Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative

Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy  Quiver Quantitative

Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February  GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire

Click here to get full coverage on Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings - RTTNews

Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings  RTTNews

Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings - RTTNews

Click here to get full coverage on Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com

Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock  Investing.com

Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com

Click here to get full coverage on Lexeo Therapeutics Announces Closing of Public Offering and - GlobeNewswire

Lexeo Therapeutics Announces Closing of Public Offering and  GlobeNewswire

Lexeo Therapeutics Announces Closing of Public Offering and - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 - Yahoo Finance

Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006  Yahoo Finance

Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 - Yahoo Finance

Click here to get full coverage on Top Brass at Biotech Player Quietly Cash Out in Latest Insider Move - TipRanks

Top Brass at Biotech Player Quietly Cash Out in Latest Insider Move  TipRanks

Top Brass at Biotech Player Quietly Cash Out in Latest Insider Move - TipRanks

Click here to get full coverage on Lexeo Therapeutics Announces Key Executive Leadership Changes - TipRanks

Lexeo Therapeutics Announces Key Executive Leadership Changes  TipRanks

Lexeo Therapeutics Announces Key Executive Leadership Changes - TipRanks

Click here to get full coverage on Lexeo Therapeutics Announces Head of Research Transition - TipRanks

Lexeo Therapeutics Announces Head of Research Transition  TipRanks

Lexeo Therapeutics Announces Head of Research Transition - TipRanks

Click here to get full coverage on Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase I/II  GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks

Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results  TipRanks

Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks

Click here to get full coverage on Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com

Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating  Investing.com

Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com

Click here to get full coverage on Lexeo Therapeutics Announces $80 Million Equity Financing - GlobeNewswire

Lexeo Therapeutics Announces $80 Million Equity Financing  GlobeNewswire

Lexeo Therapeutics Announces $80 Million Equity Financing - GlobeNewswire

Click here to get full coverage on Pharma Frenzy: Volatility Ignites Biotech Sector - MarketBeat

Pharma Frenzy: Volatility Ignites Biotech Sector  MarketBeat

Pharma Frenzy: Volatility Ignites Biotech Sector - MarketBeat

Click here to get full coverage on Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights - GlobeNewswire

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights  GlobeNewswire

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics to Present Data on AAV Manufacturing at ASGCT Annual Meeting - Quiver Quantitative

Lexeo Therapeutics to Present Data on AAV Manufacturing at ASGCT Annual Meeting  Quiver Quantitative

Lexeo Therapeutics to Present Data on AAV Manufacturing at ASGCT Annual Meeting - Quiver Quantitative

Click here to get full coverage on Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria

Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating By Investing.com  Investing.com Nigeria

Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria

Click here to get full coverage on Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Yahoo Finance

Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation  Yahoo Finance

Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on LXEO - Lexeo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

LXEO - Lexeo Therapeutics Inc Latest Stock News & Market Updates  Stock Titan

LXEO - Lexeo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - TradingView

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study  TradingView

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - TradingView

Click here to get full coverage on 3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts - TipRanks

3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts  TipRanks

3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts - TipRanks

Click here to get full coverage on Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data - Nasdaq

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data  Nasdaq

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data - Nasdaq

Click here to get full coverage on Lexeo Therapeutics Announces Pricing of Initial Public Offering - Yahoo Finance

Lexeo Therapeutics Announces Pricing of Initial Public Offering  Yahoo Finance

Lexeo Therapeutics Announces Pricing of Initial Public Offering - Yahoo Finance

Click here to get full coverage on Why This Top-Notch Biotech Stock Just Collapsed 26% - Investor's Business Daily

Why This Top-Notch Biotech Stock Just Collapsed 26%  Investor's Business Daily

Why This Top-Notch Biotech Stock Just Collapsed 26% - Investor's Business Daily

Click here to get full coverage on Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy - Stock Titan

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy  Stock Titan

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy - Stock Titan

Click here to get full coverage on Lexeo drops share price at last minute in attempt to raise $100M IPO - Fierce Biotech

Lexeo drops share price at last minute in attempt to raise $100M IPO  Fierce Biotech

Lexeo drops share price at last minute in attempt to raise $100M IPO - Fierce Biotech

Click here to get full coverage on Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results  GlobeNewswire

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics Launches $100M IPO to Fund Cardio, Alzheimer’s Candidates - BioSpace

Lexeo Therapeutics Launches $100M IPO to Fund Cardio, Alzheimer’s Candidates  BioSpace

LXEO

Price Chart

Key Statistics

Technicals

About LXEO

Latest News

LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView

Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Yahoo Finance

LXEO (NASDAQ: LXEO) Form 144: Insider files to sell 3,016 vested shares - Stock Titan

Advanced Charts

Top Gainers

Top Losers